Special Issue "The Role of the Cytoskeleton in Tumor Progression"
Deadline for manuscript submissions: 31 May 2024 | Viewed by 1571
The cytoskeleton is an organized, dynamic meshwork of protein filaments that reinforce cell membranes, provide cell shape and structural integrity, and facilitate essential cellular functions. The eukaryotic cytoskeleton is composed of three classes of filamentous fibers: actin filaments, intermediate filaments, and microtubules. Cells utilize a dynamic cytoskeleton to generate force that propels them into and through the extracellular space. Cytoskeletal filament polymerization and/or tractional tension generated against existing filaments provides that force. Differences in ECM adhesions, actin protrusions, and actomyosin contractility characterize cellular motility patterns (i.e., amoeboid, collective, mesenchymal motility). These features are dictated by differences in gene expression, signaling activity, and environmental factors.
Loss of control over cellular motility pathways is a central feature of malignancy. Dynamic remodeling of both the actin and microtubule cytoskeletal systems is required for microstructural and macrostructural patterns for tumor cell invasion. Understanding the contributions of mechanisms underlying dynamic cytoskeleton remodeling in motile cancer cells will support generation of therapeutics targeting cancer cell motility to aid in the control of tumor progression. This Special Issue seeks to highlight the current state of the art in basic and (pre)clinical cytoskeleton research in tumor cell motility, including understanding the formation of pro-invasion cytoskeletal structures (e.g., invadopodia, tumor microtubes, or tunneling nanotubes, amongst others) which may contribute to therapeutic resistance and disease progression.
Prof. Dr. Kathryn M. Eisenmann
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Rho GTPase
- tumor microtube
- tunneling nanotube
- targeted therapy
- tumor progression